Rigel Pharmaceuticals (RIGL) Other financing activities (2014 - 2026)

Rigel Pharmaceuticals' Other financing activities history runs 13 years deep, the most recent figure standing at $321000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 33.68% year-over-year to $321000.0 in Q1 2026; TTM through Mar 2026 was $7.9 million, a 236.5% increase from a year earlier, with the FY2025 full-year figure at $8.1 million, up 312.47% from the prior year.
• Other financing activities slipped to $321000.0 in Q1 2026 per RIGL's latest filing, from $2.9 million in the prior quarter.
• Across five years, Other financing activities topped out at $4.3 million in Q3 2025 and bottomed at $1000.0 in Q1 2023.
• The 5-year median for Other financing activities is $485000.0 (2023), against an average of $847437.5.
• Across the five-year window, Other financing activities tumbled 99.89% in 2023 and soared 8800.0% in 2024, its largest moves.
• Year by year, Other financing activities stood at $585000.0 in 2022, then decreased by 16.92% to $486000.0 in 2023, then surged by 201.44% to $1.5 million in 2024, then soared by 99.86% to $2.9 million in 2025, then sank by 89.04% to $321000.0 in 2026.
• Per Business Quant, the three latest RIGL Other financing activities figures stand at $321000.0 (Q1 2026), $2.9 million (Q4 2025), and $4.3 million (Q3 2025).